Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) condition involving numerous potential causative factors (e.g. alterations in gut microbiota, motility, brain–gut axis). Several interventions are available for the management of patients with IBS, but no universal management algorithm currently exists. The aim of this article is to review interventions that may be considered in the management of patients with IBS with diarrhea (IBS-D). Nonpharmacological interventions include dietary and lifestyle modification, which are generally used as first-line therapy. Probiotics have demonstrated efficacy and safety in patients with IBS, but studies are inconsistent in strains examined, dosing, and treatment duration. Psychological therapies (e.g. cognitive behavioral therapy, hypnotherapy) also may improve IBS symptoms. Pharmacological interventions for the management of IBS-D include the US Food and Drug Administration–approved agents eluxadoline, rifaximin, and alosetron, as well as loperamide, smooth muscle antispasmodics, bile acid sequestrants, and antidepressants (i.e. tricyclic antidepressants, selective serotonin reuptake inhibitors). Eluxadoline and rifaximin have been shown to improve abdominal pain and stool consistency in patients with IBS-D. In addition, data indicate that alosetron improves IBS symptoms; however, it is approved only for women with severe IBS-D. Of the three approved agents, rifaximin has the most favorable safety profile. The risk–benefit ratio is an important consideration with every medication, but is especially important in the treatment of functional GI disorders such as IBS-D. Thus, the most troublesome symptoms, quality of life, symptom intensity, and individual patient preferences should be considered when formulating a management plan for patients with IBS-D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
Self-citationFord, A. C., Lacy, B. E., Harris, L. A., Quigley, E. M. M., & Moayyedi, P. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0222-5 · Cited by 467
Self-citationAmerican College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Self-citationDionne, J., Ford, A. C., Yuan, Y., Chey, W. D., Lacy, B. E., Saito, Y. A., Quigley, E. M. M., & Moayyedi, P. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0195-4 · Cited by 379
Self-citationEluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Self-citationLembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
Slattery, S. A., Niaz, O., Aziz, Q., Ford, A. C., & Farmer, A. D. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13227 · Cited by 214
Cited by
Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome
Chey, W. D., Keefer, L., Whelan, K., & Gibson, P. R. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.06.099 · Cited by 154
Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders
Barbaro, M. R., Cremon, C., Wrona, D., Fuschi, D., Marasco, G., Stanghellini, V., & Barbara, G. (2020) · Nutrients · doi:10.3390/nu12123735 · Cited by 66
Barraza-Ortiz, D. A., Pérez-López, N., Medina-López, V. M., Minero-Alfaro, J. I., Zamarripa-Dorsey, F., Fernández-Martínez, N. D. C., Llorente-Ramón, A., & Ramos-Aguilar, G. A. (2021) · Digestive Diseases · doi:10.1159/000510950 · Cited by 32
Metadata
- Authors
- Cangemi, D. J., & Lacy, B. E.
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 12
- Pages
- 1756284819878950-1756284819878950
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- OpenAlex
- W2978802363
- Cited by
- 75
- References
- 18
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. https://app.cochat.ai/papers/10.1177/1756284819878950
- The paper
- Cangemi, D. J., & Lacy, B. E. (2019). Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756284819878950
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.